Safety Study With Paliperidone ER Extended-Release (ER) Tablets in Geriatric Patients With Schizophrenia
Schizophrenia
About this trial
This is an interventional treatment trial for Schizophrenia focused on measuring schizophrenia, geriatric, elderly
Eligibility Criteria
Inclusion Criteria: Double-Blind Phase: 65 years of age or older DSM-IV diagnosis of schizophrenia for at least 1 year total PANSS score at screening and baseline between 70 and 120, inclusive agrees to hospitalization for a minimum of 14 days and for the duration of the study, if clinically indicated Open-label treatment phase: completed 6 weeks of the double-blind treatment phase or finished at least 21 days of treatment and discontinued because of lack of efficacy. Exclusion Criteria: DSM-IV Axis I diagnosis other than schizophrenia DSM-IV diagnosis of substance dependence within the 6 months before screening (nicotine and caffeine dependence are not exclusionary) history of tardive dyskinesia or neuroleptic malignant syndrome (NMS) history of any severe preexisting severe gastrointestinal narrowing (pathologic or iatrogenic) previous history of a lack of response (2 adequate trials) to any antipsychotic